Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxybutynin vs Paroxetine for AI-induced Vasomotor Symptoms in Breast Cancer
NCT05637671Phase 3Unknown
- Sponsor
- Cairo University
- Start
- Feb 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of oxybutynin in vasomotor symptoms, sponsored by Cairo University. Status: unknown.
02
Drugs
oxybutynin
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT05637671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05637671.